Literature DB >> 31392160

How to guide the selection of patients for trimodality therapy: the case for tumor immune and stromal signature.

Luca Boeri1,2, R Jeffrey Karnes2, Emanuele Montanari1.   

Abstract

Entities:  

Year:  2019        PMID： 31392160      PMCID： PMC6642950          DOI： 10.21037/tau.2019.05.10

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  20 in total

1.  Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.

Authors:  Nicholas J Giacalone; William U Shipley; Rebecca H Clayman; Andrzej Niemierko; Michael Drumm; Niall M Heney; Marc D Michaelson; Richard J Lee; Philip J Saylor; Matthew F Wszolek; Adam S Feldman; Douglas M Dahl; Anthony L Zietman; Jason A Efstathiou
Journal:  Eur Urol       Date:  2017-01-09       Impact factor: 20.096

Review 2.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 3.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Authors:  Claire Vanpouille-Box; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

Review 4.  Evolving adoptive cellular therapies in urological malignancies.

Authors:  Yien Ning Sophia Wong; Kroopa Joshi; Martin Pule; Karl S Peggs; Charles Swanton; Sergio A Quezada; Mark Linch
Journal:  Lancet Oncol       Date:  2017-06       Impact factor: 41.316

5.  Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

Authors:  Sam S Chang; Bernard H Bochner; Roger Chou; Robert Dreicer; Ashish M Kamat; Seth P Lerner; Yair Lotan; Joshua J Meeks; Jeff M Michalski; Todd M Morgan; Diane Z Quale; Jonathan E Rosenberg; Anthony L Zietman; Jeffrey M Holzbeierlein
Journal:  J Urol       Date:  2017-04-26       Impact factor: 7.450

6.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Authors:  Roland Seiler; Hussam Al Deen Ashab; Nicholas Erho; Bas W G van Rhijn; Brian Winters; James Douglas; Kim E Van Kessel; Elisabeth E Fransen van de Putte; Matthew Sommerlad; Natalie Q Wang; Voleak Choeurng; Ewan A Gibb; Beatrix Palmer-Aronsten; Lucia L Lam; Christine Buerki; Elai Davicioni; Gottfrid Sjödahl; Jordan Kardos; Katherine A Hoadley; Seth P Lerner; David J McConkey; Woonyoung Choi; William Y Kim; Bernhard Kiss; George N Thalmann; Tilman Todenhöfer; Simon J Crabb; Scott North; Ellen C Zwarthoff; Joost L Boormans; Jonathan Wright; Marc Dall'Era; Michiel S van der Heijden; Peter C Black
Journal:  Eur Urol       Date:  2017-04-05       Impact factor: 20.096

Review 7.  Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.

Authors:  Heather Katz; Emnet Wassie; Mohamed Alsharedi
Journal:  Med Oncol       Date:  2017-09-01       Impact factor: 3.064

8.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Authors:  Phillip J Gray; Stacey A Fedewa; William U Shipley; Jason A Efstathiou; Chun Chieh Lin; Anthony L Zietman; Katherine S Virgo
Journal:  Eur Urol       Date:  2012-11-19       Impact factor: 20.096

Review 9.  ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.

Authors:  Georgios Gakis; Jason Efstathiou; Seth P Lerner; Michael S Cookson; Kirk A Keegan; Khurshid A Guru; William U Shipley; Axel Heidenreich; Mark P Schoenberg; Arthur I Sagaloswky; Mark S Soloway; Arnulf Stenzl
Journal:  Eur Urol       Date:  2012-08-14       Impact factor: 20.096

10.  Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

Authors:  Alexandra Snyder; Tavi Nathanson; Samuel A Funt; Arun Ahuja; Jacqueline Buros Novik; Matthew D Hellmann; Eliza Chang; Bulent Arman Aksoy; Hikmat Al-Ahmadie; Erik Yusko; Marissa Vignali; Sharon Benzeno; Mariel Boyd; Meredith Moran; Gopa Iyer; Harlan S Robins; Elaine R Mardis; Taha Merghoub; Jeff Hammerbacher; Jonathan E Rosenberg; Dean F Bajorin
Journal:  PLoS Med       Date:  2017-05-26       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.